About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Dr. Kevin P. Francis Ph.D, PerkinElmer Fellow and Visiting Professor at UCLA and Texas A&M / Dr. Guillaume Reveillon, PhD Field Application Specialist PerkinElmer
According to the World Health Organization, infectious diseases are estimated to cause a quarter of all deaths globally. Moreover, the risk of new pathogens emerging and evolving to monopolize on the ever-expanding global human population is increasing year-on-year. The recent COVID-19 viral pandemic, although devastating from both a social and economic standpoint, was relatively minor compared to prior viral and bacterial ‘plagues’ that have reshaped civilizations throughout history.
Each year more than 70 billion standard units of antibiotic are prescribed to treat bacterial infections worldwide. In addition, around 80,000 tons of antibiotics are consumed by livestock for growth promotion and disease prevention. The result of this overuse of antibiotics is a spiraling increase in resistance. Bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) have increased in prevalence in hospitals over the last three decades. Such bacteria are particularly problematic in postoperative infections, exacerbating treatment through the development of biofilms, especially on medical implants which are extremely hard to treat without removal and replacement of the device.
This presentation will show how noninvasive preclinical optical imaging is being used to better understand the establishment and development of infections in a range of different animal disease models, including post-operative infections
Host: Dr. Anna Santamaria, Biomedical Research in Urology group.
Online Connection: https://gencat.zoom.us/j/94191432677